Key clinical point: Peripheral perfusion would provide a simple, physiologically targeted alternative to lactate level.

Major finding: Survival was no better, but mean SOFA score was lower (5.6 vs. 6.6).

Study details: Randomized, controlled trial (n = 416).

Disclosures: The study received no external funding. Dr. Hernández and Dr. Bakker had no relevant financial disclosures. Dr. Angus received consulting fees from Ferring Pharmaceutical, Bristol-Myers Squibb, Bayer AG, and others outside the submitted work; he also has patents pending for compounds, compositions, and methods for treating sepsis and for proteomic biomarkers.